Biocon Biologics is set to introduce new biosimilar oncology assets, including biosimilars for Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company also plans integration as a wholly owned subsidiary into Biocon Ltd., strengthening its leadership in biosimilar insulins and GLP-1 peptide generics to cover the full spectrum of diabetes care. This strategic vision will be outlined at the 2026 J.P. Morgan Healthcare Conference.
Oncology Portfolio Expansion
Biocon Biologics will introduce three new biosimilar oncology assets: Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®). This expansion strengthens its cancer portfolio, making it one of the most comprehensive in the industry.
Global sales data for these therapies highlights the market opportunity: Keytruda sales were $29.5 billion in 2024, Opdivo sales were $9.3 billion in 2024, and Herceptin SC/Herceptin HYLECTA combined sales were $1.72 billion in 2024. These assets, joining Biocon’s existing portfolio, represent an over $75 billion opportunity, or approximately 35% of the global oncology pharmaceutical market.
Corporate Integration Plans
Biocon Limited will integrate Biocon Biologics as a wholly owned subsidiary, combining the businesses to leverage global commercial infrastructure. This integration aims to simplify the corporate structure and strengthen Biocon’s global position in diabetes, oncology, and immunology, therapeutic areas that account for nearly 40% of global pharmaceutical revenues.
The integration is expected to be completed by March 31, 2026. Biocon will uniquely offer both biosimilar insulins and generics for complex peptides, including GLP-1s, to address diabetes care. The company aims to deliver affordable medicines to over 6 million patients in more than 120 markets worldwide.
Leadership Remarks
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, stated that the integration strengthens Biocon Biologics’ ability to deliver biosimilars and generics at global scale. He also noted the advancement of a strong pipeline with 17 oncology assets.
J.P. Morgan Healthcare Conference
Shreehas Tambe will present at the J.P. Morgan Healthcare Conference on Thursday, January 15, 2026. A live audio webcast will be available online.
Source: BSE
